KMDA

Kamada Ltd.

8.48 USD

Last updated Sep 4, 19:45 UTC

Yesterday HIGH

$8.34

Yesterday LOW

$8.22

52w HIGH

$9.35

52w LOW

$6.5

EPS

0.16

PE

53.00

Next Earnings

Nov 9, 2026

Overview News Insider Transactions Government Trades Fundamentals

Kamada Ltd. stock is up 18.11% since 30 days ago. The next earnings date is Nov 9, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 38.46% of the previous 13 September’s closed higher than August.

Benzinga Newsdesk

Wed Aug 12, 2026

Kamada Affirms FY2026 Sales Guidance of $200.000M-$205.000M vs $202.048M Est

Kamada (NASDAQ:KMDA) affirms FY2026 sales outlook from $200.000 million-$205.000 million to $200.000 million-$205.000 million vs $202.048 million estimate.
Benzinga Newsdesk

Wed Aug 12, 2026

Kamada Q2 EPS $0.16 Beats $0.12 Estimate, Sales $54.921M Beat $50.657M Estimate

Kamada (NASDAQ:KMDA) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.12 by 33.33 percent. This is a 23.08 percent increase over earnings of $0.13 per share from the same
Benzinga Newsdesk

Mon Jul 20, 2026

Kamada Signs $50M Plasma Supply Agreement With Biopharma Partner Through Texas Centers, Commercial Sales Starting Q4 2026

Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today
Benzinga Newsdesk

Mon Jul 13, 2026

Kamada Highlights Results Of An Investigator-initiated Study Of Cytogam, The Company’s Cytomegalovirus Immune Globulin, In The Management Of Cytomegalovirus In Solid Organ Transplantation

Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies
Benzinga Newsdesk

Mon Jun 1, 2026

Kamada Announces FDA Approval Of New In-House Rapid Fluorescent Focus Inhibition Test Laboratory

Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field,
Benzinga Newsdesk

Wed May 13, 2026

Kamada shares are trading lower after the company reported worse-than-expected Q1 financial results.
Benzinga Insights

Wed May 13, 2026

Kamada Q1 2026 Earnings Call: Complete Transcript
Benzinga Insights

Wed May 13, 2026

Earnings Scheduled For May 13, 2026
Benzinga Newsdesk

Wed May 13, 2026

Kamada Affirms FY2026 Sales Guidance of $200.000M-$205.000M vs $201.581M Est

Kamada (NASDAQ:KMDA) affirms FY2026 sales outlook from $200.000 million-$205.000 million to $200.000 million-$205.000 million vs $201.581 million estimate.
Benzinga Newsdesk

Wed May 13, 2026

Kamada Q1 EPS $0.07 Misses $0.12 Estimate, Sales $45.240M Miss $46.722M Estimate

Kamada (NASDAQ:KMDA) reported quarterly earnings of $0.07 per share which missed the analyst consensus estimate of $0.12 by 41.67 percent. This is unchanged from the same period last year. The company reported quarterly

Yael Brenner, VP Quality

Wed Aug 26, 2026

KMDA Recent Insider Trades and Stock Chart

60,000 shares converted
Karnit Goldwasser, Director

Wed Aug 5, 2026

KMDA Recent Insider Trades and Stock Chart

30,000 shares awarded
Uri Botzer, Director

Wed Aug 5, 2026

KMDA Recent Insider Trades and Stock Chart

30,000 shares awarded
Lilach Asher Topilsky, Director

Wed Aug 5, 2026

KMDA Recent Insider Trades and Stock Chart

30,000 shares awarded
David Tsur, Director

Wed Aug 5, 2026

KMDA Recent Insider Trades and Stock Chart

30,000 shares awarded
Benjamin Dekel, Director

Wed Aug 5, 2026

KMDA Recent Insider Trades and Stock Chart

30,000 shares awarded
Ishay Davidi, Director

Wed Aug 5, 2026

KMDA Recent Insider Trades and Stock Chart

30,000 shares awarded
Assaf Itshayek, Director

Wed Aug 5, 2026

KMDA Recent Insider Trades and Stock Chart

30,000 shares awarded
Leon Recanati, Director

Wed Aug 5, 2026

KMDA Recent Insider Trades and Stock Chart

30,000 shares awarded
Lilach Payorski, Director

Wed Aug 5, 2026

KMDA Recent Insider Trades and Stock Chart

30,000 shares awarded